A5079116736- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Epigenetics and DNA Methylation
- Zebrafish Biomedical Research Applications
- Monoclonal and Polyclonal Antibodies Research
- Prostate Cancer Treatment and Research
- Thyroid Cancer Diagnosis and Treatment
- Melanoma and MAPK Pathways
- Hippo pathway signaling and YAP/TAZ
- Cancer-related Molecular Pathways
- Synthesis and Biological Evaluation
- Acute Myeloid Leukemia Research
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- CRISPR and Genetic Engineering
- FOXO transcription factor regulation
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- CAR-T cell therapy research
- BRCA gene mutations in cancer
- Radiopharmaceutical Chemistry and Applications
- Genomics and Chromatin Dynamics
- Lung Cancer Treatments and Mutations
- Single-cell and spatial transcriptomics
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Regeneron (United States)
2022-2025
Cornell University
2014-2023
The University of Texas MD Anderson Cancer Center
2023
Roche (Switzerland)
2023
Weill Cornell Medicine
2021-2023
Icahn School of Medicine at Mount Sinai
1997-2023
New York Hospital Queens
2011-2022
NewYork–Presbyterian Hospital
2011-2022
Presbyterian Hospital
2011-2022
Lander Institute
2021
RET fusions are present in 1%-2% of non-small-cell lung cancer (NSCLC). Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective inhibitor, previously demonstrated clinical activity patients with fusion-positive NSCLC the phase I/II ARROW study, including among treatment-naive patients. We report an updated analysis from study.ARROW is multi-cohort, open-label, study. Eligible were ≥18 years age locally advanced or metastatic solid tumours and Eastern Cooperative...
PURPOSE We present a phase I/II first-in-human trial evaluating the safety and efficacy of 50 mg 200 doses linvoseltamab, B-cell maturation antigen × CD3 bispecific antibody in relapsed/refractory multiple myeloma (RRMM). METHODS Phase II eligible patients had RRMM that either progressed on/after ≥three lines therapy including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 or was triple-class (PI/IMiD/anti-CD38) refractory. treatment once week through 14 then every 2...
Genomic instability is a fundamental feature of human cancer often resulting from impaired genome maintenance. In prostate cancer, structural genomic rearrangements are common mechanism driving tumorigenesis. However, somatic alterations predisposing to chromosomal in remain largely undefined. Here, we show that SPOP , the most commonly mutated gene primary modulates DNA double strand break (DSB) repair, and mutation associated with instability. vivo, results transcriptional response...
A phase 1 study was initiated to determine the safety, potential effectiveness, and maximal tolerated dose recommended 2 of efatutazone paclitaxel in anaplastic thyroid cancer.Patients received (0.15, 0.3, or 0.5 mg) orally twice daily then every 3 weeks. Patient tolerance outcomes were assessed, as serum pharmacokinetics.Ten 15 patients women. Median age 59 years. Seven 0.15 mg efatutazone, 6 0.3 mg, mg. One patient receiving had a partial response from day 69 175; 7 attained stable...
Abstract Cancers contain a wide diversity of cell types that are defined by differentiation states, genetic mutations and altered epigenetic programmes impart functional to individual cells. Elevated tumour heterogeneity is linked with progression, therapy resistance relapse. Yet, imaging the hallmarks cancer has been technical biological challenge. Here we develop optically clear immune-compromised rag2 E450fs (casper) zebrafish for optimized transplantation direct visualization...
8006 Background: Linvoseltamab is a BCMA×CD3 bispecific antibody with encouraging efficacy and manageable safety profile in patients (pts) relapsed/refractory multiple myeloma (RRMM) (Bumma et al. ASH 2022). Two Phase (Ph) 2 full dose cohorts (50 mg 200 mg) the LINKER-MM1 (NCT03761108) trial were studied to optimize selection. Methods: Ph enrolled adults MM who progressed on/after ≥3 lines of therapy (LoT) including proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 (Ab),...
Regulatory T (T reg) cells are a specialized sublineage of lymphocytes that suppress autoreactive cells. Functional studies reg in vitro have defined multiple suppression mechanisms, and reg-deficient humans mice made clear the important role these play preventing autoimmunity. However, many questions remain about how act vivo. Specifically, it is not which mechanisms most important, where act, they get there. To begin to address issues, we sought identify zebrafish, model system provides...
Oncogenomic studies indicate that copy number variation (CNV) alters genes involved in tumor progression; however, identification of specific driver affected by CNV has been difficult, as these rearrangements are often contained large chromosomal intervals among several bystander genes. Here, we addressed this problem and identified a CNV-targeted oncogene performing comparative oncogenomics human zebrafish melanomas. We determined the gene encoding growth differentiation factor 6 (GDF6),...
Significance Dietary selenium and selenoproteins play important roles in regulating redox processes that impact human health. The genome includes 25 genes for selenoproteins, which have diverse homeostasis, thyroid hormone metabolism, endoplasmic reticulum quality control, transport, other functions. Selenoprotein H ( seph ) is a recently identified nucleolar oxidoreductase with DNA-binding properties whose function not well understood. In this work, we used unique combination of unbiased...
Thyroid cancer is common, yet the sequence of alterations that promote tumor formation are incompletely understood. Here, we describe a novel model thyroid carcinoma in zebrafish reveals temporal changes due to BRAF V600E . Through use real-time vivo imaging, observe disruption follicle structure occurs early development. Combinatorial treatment using and MEK inhibitors reversed developmental effects induced by Adult expressing thyrocytes developed invasive carcinoma. We identified gene...
Prenatal alcohol exposure (PAE) affects at least 10% of newborns globally and leads to the development fetal spectrum disorders (FASDs). Despite its high incidence, there is no consensus on implications PAE metabolic disease risk in adults. Here, we describe a cohort adults with FASDs that had an increased incidence abnormalities, including type 2 diabetes, low HDL, triglycerides, female-specific overweight obesity. Using zebrafish model for PAE, performed population studies elucidate seen...
Abstract CRISPR/Cas9 has become a powerful tool for genome editing in zebrafish that permits the rapid generation of loss function mutations and knock-in specific alleles using DNA templates homology directed repair (HDR). We examined efficiency synthetic, chemically modified gRNAs demonstrate induction indels large genomic deletions combination with recombinant Cas9 protein. developed an vivo genetic assay to measure HDR we utilized this test effect altering template design on HDR....
Abstract Background We report pivotal results from the registrational filing data cut-off (DCO) of 200 mg dose used in LINKER-MM1 (NCT03761108) clinical trial, testing safety and efficacy linvoseltamab (a B-cell maturation antigen × CD3 antibody [Ab]) as treatment for relapsed/refractory multiple myeloma (RRMM). Methods Eligible patients had RRMM that either progressed on/after ≥3 lines therapy included a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), anti-CD38 Ab or was...
Abstract Clonal hematopoiesis (CH) refers to the expansion of certain blood cell lineages and has been associated with aging adverse health outcomes. Here, we use exome sequence data on 628,388 individuals identify 40,208 carriers clonal indeterminate potential (CHIP). Using genome-wide exome-wide association analyses, 27 loci (24 novel) where germline genetic variation influences CH/CHIP predisposition, including missense variants in DNA-repair gene PARP1 lymphocytic antigen coding LY75...